Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Evoke Pharma Inc | evok-ex322_9.htm |
| EX-32.1 - EX-32.1 - Evoke Pharma Inc | evok-ex321_10.htm |
| EX-31.2 - EX-31.2 - Evoke Pharma Inc | evok-ex312_8.htm |
| EX-31.1 - EX-31.1 - Evoke Pharma Inc | evok-ex311_11.htm |
| EX-10.26 - EX-10.26 - Evoke Pharma Inc | evok-ex1026_373.htm |
| EX-4.9 - EX-4.9 - Evoke Pharma Inc | evok-ex49_632.htm |
| 10-K - 10-K - Evoke Pharma Inc | evok-10k_20191231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Evoke Pharma, Inc.
Solana Beach, California
We hereby consent to the incorporation by reference in Registration Statements on Form S-3 (No. 333-221556) and Form S-8 (Nos. 333-224897, 333-219960, 333-211302 and 333-191518) of Evoke Pharma, Inc. (the “Company”) of our report dated March 12, 2020, relating to the financial statements, which appears in this Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
/s/ BDO USA, LLP
San Diego, California
March 12, 2020